Naslov
The Euromelanoma skin cancer prevention campaign in Europe: characteristics and resultrs of 2009 and 2010

Autori
Van der Leest, R.J. ; de Vries, E. ; Bulliard, J.L. ; Paoli, J. ; Peris, K. ; Stratigos, A.J. ; Trakatelli, M. ; Maselis, T.J. ; Šitum, Mirna ; Pallouras, A.C. ; Hercogova, J. ; Zafirovik, Z. ; Reusch, M. ; Olah, J. ; Bylaite, M. ; Dittmar, H.C. ; Scerri, L. ; Correia, O. ; Medenica, L. ; Bartenjev, I. ; Guillen, C. ; Cozzio, A. ; Bogomolets, O.V. ; Del Marmol, V.

Izvornik
JEADV. Journal of the European Academy of Dermatology and Venereology (0926-9959) 25 (2011), 12; 1455-1465

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Euromelanoma ; skin cancer ; skin cancer prevention

Sažetak
Euromelanoma is a skin cancer education and prevention campaign that started in 1999 in Belgium as ‘Melanoma day’. Since 2000, it is active in a large and growing number of European countries under the name Euromelanoma. Objective was to evaluate results of Euromelanoma in 2009 and 2010 in 20 countries, describing characteristics of screenees, rates of clinically suspicious lesions for skin cancer and detection rates of melanomas. Euromelanoma questionnaires were used by 20 countries providing their data in a standardized database (Belgium, Croatia, Cyprus, Czech Republic, FYRO Macedonia, Germany, Greece, Hungary, Italy, Lithuania, Luxembourg, Malta, Moldavia, Portugal, Serbia, Slovenia, Spain, Sweden, Switzerland and Ukraine). In total, 59 858 subjects were screened in 20 countries. Most screenees were female (64%), median ages were 43 (female) and 46 (male) and 33% had phototype I or II. The suspicion rates ranged from 1.1% to 19.4% for melanoma (average 2.8%), from 0.0% to 10.7% for basal cell carcinoma (average 3.1%) and from 0.0% to 1.8% for squamous cell carcinoma (average 0.4%). The overall positive predictive value of countries where (estimation of) positive predictive value could be determined was 13.0%, melanoma detection rates varied from 0.1% to 1.9%. Dermoscopy was used in 78% of examinations with clinically suspected melanoma ; full body skin examination was performed in 72% of the screenees. Although the population screened during Euromelanoma was relatively young, high rates of clinically suspected melanoma were found. The efficacy of Euromelanoma could be improved by targeting high-risk populations and by better use of dermoscopy and full body skin examination.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA